Swapna Thota, MD Swapna Thota, MD

Swapna Thota

MD

Specializing In:

Acute leukemias Myeloproliferative neoplasms Myelodysplastic syndrome Aplastic anemia/ PNH Acquired bone marrow failure conditions

Special Interests:

Myeloproliferative syndromes Myelodysplastic syndromes Molecular biology of myeloid malignancies

About Me

Biography:

I joined Roswell Park in 2017. I specialize in taking care of patients with acute leukemias, myelodysplastic syndromes and other blood cancers. I completed my residency at Fairview hospital, Cleveland and fellowship training at Cleveland Clinic's Taussig Cancer Institute. I am board certified in Internal Medicine and board eligible for Hematology/Medical Oncology. I am also a member of multiple professional organizations including American Society of Clinical Oncology, American Society of Hematology and American College of Physicians.

In terms of my research, as a clinical investigator trained with a specific focus in hematologic malignancies, I am interested in novel drug development to improve outcomes in patients with blood cancers. Specifically, I investigate biomarker-driven or modern targeted therapies for treating hematologic malignancies. I hope to translate novel findings from the lab to the patients by conducting early phase clinical trials.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Medicine
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo
  • Assistant Professor of Medicine

Background

Education and Training:

  • MD - Osmania Medical College, India

Residency:

  • Internal Medicine, Cleveland Clinic, Fairview

Fellowship:

  • Experimental Therapeutic (MDS/Leukemia): Cleveland Clinic, Taussig Cancer Institute
  • Hematology & Oncology: Cleveland Clinic, Taussig Cancer Institute

Board Certification:

  • Internal Medicine

Professional Memberships:

  • 2013 - present: American Society of Hematology (ASH)
  • 2013 - present: American Society of Clinical Oncology (ASCO)
  • 2010 - present: American College of Physicians (ACP)

Honors & Awards

  • 2016 - Selected for AACR/ASCO Methods In Clinical Cancer Research Workshop: “ A Phase II trial of single agent metformin in TET2 mutated low risk MDS patients”
  • 2014 - Awarded Clinical Excellence in MDS from Edward P. Evan’s MDS Clinical Research Consortium for successful completion of MDS/Leukemia research fellowship and for translational research conducted.
  • 2014: Abstract Achievement Award from American Society of Hematology
  • 2013 - Abstract Achievement Award from American Society of Hematology for two oral presentations
  • 2013 - Best Abstract Award for oral presentation on “ Outcomes of small cell carcinoma of urinary bladder - a Cleveland Clinic experience” Department of Internal Medicine, Fairview- Cleveland Clinic
  • 2012 - Caregiver Celebration Award, for excellence in clinical care from Cleveland Clinic
  • 2011 - Awarded American College of Physicians Merit Award and selected as Poster Finalist
  • 2011 - Caregiver Celebration Award, for excellence in clinical care from Cleveland Clinic

Publications

Full Publications list on PubMed
  • Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Bilori B, Thota S, Clemente MJ, Patel B, Jerez A, Afable Ii M, Maciejewski JP. Leukemia. 2015 Dec;29(12):2427-9.
  • Genetic alterations of the cohesin complex genes in myeloid malignancies. Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, Sekeres MA, Levine RL, Maciejewski JP. Blood. 2014 Sep 11;124(11):1790-8.
  • Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, Hirsh C, Viny AD, Hosano N, Bleeker FE, Meggendorfer M, Alpermann T, Shiraishi Y, Chiba K, Tanaka H, van Noorden CJ, Radivoyevitch T, Carraway HE, Makishima H, Miyano S, Sekeres MA, Ogawa S, Haferlach T, Maciejewski JP. Leukemia. 2015 Nov;29(11):2134-42.
  • Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Thota S, Advani A. Eur J Haematol. 2017 May;98(5):425-434
  • Therapeutic outcomes using low dose alemtuzumab for acquired bonemarrow failure conditions. Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres M, Risitano A, Maciejewski JP. British J Hematol, 2017 Aug (in press)

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment

See what others are saying about their care and leave your own review.

Leave a Review